A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study

BACKGROUND: Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients. METHODS: Eligible patients had at least one prior c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Chan, John K., Deng, Wei, Higgins, Robert V., Tewari, Krishnansu S., Bonebrake, Albert J., Hicks, Michael, Gaillard, Stephanie, Ramirez, Pedro T., Chafe, Weldon, Monk, Bradley J., Aghajanian, Carol
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728988/
https://ncbi.nlm.nih.gov/pubmed/28728751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.05.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados